• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Low Wei Sim

    3/20/26 8:04:50 PM ET
    $ALPS
    Get the next $ALPS alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Low Wei Sim

    (Last)(First)(Middle)
    UNIT E18-01&02, LVL 18, ICON TWR E
    NO. 1, JALAN 1/68F, JALAN TUN RAZAK

    (Street)
    KUALA LUMPUR00000

    (City)(State)(Zip)

    MALAYSIA

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Alps Group Inc [ ALPS ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Operating Officer
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Ordinary Shares821,083D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    /s/ Low Wei Sim03/20/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $ALPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mohamed Suleiman Bin

    3 - Alps Group Inc (0002025774) (Issuer)

    3/20/26 8:08:38 PM ET
    $ALPS

    SEC Form 3 filed by new insider Manickam Ravichandran

    3 - Alps Group Inc (0002025774) (Issuer)

    3/20/26 8:06:15 PM ET
    $ALPS

    SEC Form 3 filed by new insider Low Wei Sim

    3 - Alps Group Inc (0002025774) (Issuer)

    3/20/26 8:04:50 PM ET
    $ALPS

    $ALPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol

    KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports. The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infusions produced using the Company's in-house developed culture protocol. Natural Killer (NK) cells are a type of immune cell involved in the body's natural defense against abnormal cells.

    2/23/26 8:00:00 AM ET
    $ALPS

    Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy

    KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinical case series in SAGE Open Medical Case Reports describing nebulized human umbilical cord mesenchymal stem cell ("hUCMSC") derived exosome in patient with asthma and/or chronic obstructive pulmonar

    1/30/26 8:00:00 AM ET
    $ALPS

    Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer

    KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ:ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as ris

    1/8/26 8:00:00 AM ET
    $ALPS

    $ALPS
    SEC Filings

    View All

    SEC Form 6-K filed by ALPS Group Inc

    6-K - Alps Group Inc (0002025774) (Filer)

    2/23/26 8:59:58 AM ET
    $ALPS

    SEC Form 6-K filed by ALPS Group Inc

    6-K - Alps Group Inc (0002025774) (Filer)

    2/4/26 9:14:49 PM ET
    $ALPS

    SEC Form 6-K filed by ALPS Group Inc

    6-K - Alps Group Inc (0002025774) (Filer)

    1/30/26 4:00:28 PM ET
    $ALPS

    $ALPS
    Leadership Updates

    Live Leadership Updates

    View All

    Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer

    KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ:ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as ris

    1/8/26 8:00:00 AM ET
    $ALPS

    $ALPS
    Financials

    Live finance-specific insights

    View All

    Alpine Summit Energy Partners Announces Full Year 2022 Financial and Operating Results

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - March 27, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") is pleased to announce its financial and operating results for the year ended December 31, 2022. Alpine Summit's audited consolidated financial statements and notes, as well as management's discussion and analysis (the "MD&A") and its Annual Report on Form 10-K for the year ended December 31, 2022 will be available under the Company's issuer profile at "www.sedar.com" and "www.sec.gov/edgar", as well as on the Company's website at "www.alpinesummitenergy.com".Craig Perry, Chief Executive Officer, remarked:

    3/27/23 7:00:00 AM ET
    $ALPS

    Alpine Summit Energy Partners Announces Strategic Review of Assets

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - February 23, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") today announced that the Board of Directors is commencing a strategic review of its assets. The Company seeks to facilitate a timely and orderly response to unsolicited inquiries by other upstream oil and gas companies who have expressed interest in acquiring various assets of the Company. The goal of the review is to maximize shareholder value and better position the Company for long-term stability and growth.Given the Company's decision to initiate this strategic review, alongside the historic volatil

    2/23/23 8:00:00 AM ET
    $ALPS

    Alpine Summit Energy Partners Announces February 2023 Dividend

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - February 1, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") is pleased to announce that, in accordance with its current monthly dividend policy, the Board of Directors of the Company has declared a dividend of US$0.0315 per subordinate voting share for the month of February 2023. Simultaneously with declaring the dividend on the subordinate voting shares, the directors also declared a dividend on the Company's multiple voting shares equal to US$3.15 per share and a dividend on the Company's proportionate voting shares equal to US$0.0315 per share.The dividend is pa

    2/1/23 8:00:00 AM ET
    $ALPS